Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OCGN 
Ocugen Inc (OCGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: OCGN (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 111% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 334.17M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 4 | Beta 4.16 | 52 Weeks Range 0.52 - 1.29 | Updated Date 09/14/2025 |
52 Weeks Range 0.52 - 1.29 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1004.73% |
Management Effectiveness
Return on Assets (TTM) -73.55% | Return on Equity (TTM) -569.99% |
Valuation
Trailing PE - | Forward PE 15.22 | Enterprise Value 339976067 | Price to Sales(TTM) 70.29 |
Enterprise Value 339976067 | Price to Sales(TTM) 70.29 | ||
Enterprise Value to Revenue 71.51 | Enterprise Value to EBITDA -1.95 | Shares Outstanding 312304992 | Shares Floating 287937703 |
Shares Outstanding 312304992 | Shares Floating 287937703 | ||
Percent Insiders 1.49 | Percent Institutions 16.63 |
Upturn AI SWOT
Ocugen Inc
Company Overview
History and Background
Ocugen Inc. was founded in 2013. Initially focused on developing therapies for eye diseases, Ocugen has shifted focus to developing and commercializing vaccines. A significant milestone was the collaboration with Bharat Biotech for Covaxin.
Core Business Areas
- Vaccine Development: Development and potential commercialization of vaccines for infectious diseases, primarily focusing on COVID-19. COVAXIN is its key candidate.
- Ophthalmology: Historically focused on ophthalmology, Ocugen maintains some legacy programs in this area but its main focus is vaccine development.
Leadership and Structure
Dr. Shankar Musunuri is the Chairman, CEO, and Co-Founder. The organizational structure is typical of a small biotechnology company with departments for research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- COVAXIN: COVID-19 vaccine developed by Bharat Biotech and co-commercialized (intended) by Ocugen in the US and Canada. COVAXIN has not received FDA approval or EUA in the US and Canada. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Vaccine development is a complex and lengthy process. The COVID-19 vaccine market is dominated by established players.
Positioning
Ocugen is a small player attempting to enter a market dominated by large, well-established pharmaceutical companies. It relies on partnerships with companies like Bharat Biotech. Their competitive advantage depends on achieving regulatory approval for COVAXIN and proving its efficacy and safety.
Total Addressable Market (TAM)
The global vaccines market is projected to reach hundreds of billions of dollars. Ocugen aims to capture a portion of the COVID-19 vaccine market but faces intense competition from established players with approved vaccines and supply chains. The TAM for COVID-19 vaccines fluctuates with pandemic conditions.
Upturn SWOT Analysis
Strengths
- Partnership with Bharat Biotech (COVAXIN)
- Potential for differentiated COVID-19 vaccine if approved
- Experienced leadership team in ophthalmology (historical strength)
Weaknesses
- Lack of FDA approval or EUA for COVAXIN in the US or Canada
- High dependence on a single product (COVAXIN)
- Limited financial resources compared to competitors
- No proprietary production capabilities
Opportunities
- Potential for FDA approval or EUA for COVAXIN
- Expansion into other vaccine development programs
- Strategic partnerships for manufacturing and distribution
- Emergence of new COVID-19 variants and need for boosters
Threats
- Failure to obtain FDA approval or EUA for COVAXIN
- Competition from established COVID-19 vaccines
- Changing COVID-19 landscape and waning demand for vaccines
- Negative clinical trial results or safety concerns
- Dilution of share value
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
- NVAX
Competitive Landscape
Ocugen faces an uphill battle against established pharmaceutical giants. Its success depends on COVAXIN proving to be a differentiated product with a unique value proposition (e.g., better safety profile, efficacy against new variants).
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited. Past growth spurts were driven by COVAXIN news and speculation.
Future Projections: Future growth depends heavily on COVAXIN's regulatory approval. Analyst estimates vary significantly based on approval probability.
Recent Initiatives: Focusing on clinical trials, regulatory submissions, and manufacturing partnerships for COVAXIN.
Summary
Ocugen is a high-risk, high-reward biotechnology company whose future heavily depends on the success of COVAXIN. While partnerships are a strength, the lack of regulatory approvals and intense competition pose significant challenges. Financial stability relies on managing cash effectively. Any positive news on regulatory approval for COVAXIN can significantly impact stock performance, while setbacks can have the opposite effect.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), press releases, analyst reports, market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The pharmaceutical industry is subject to rapid changes, and data may become outdated quickly. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocugen Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2014-12-03 | Co-Founder, CEO & Chairman Dr. Shankar Musunuri M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.ocugen.com |
Full time employees 95 | Website https://www.ocugen.com | ||
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.